Jupiter Asset Management Ltd. bought a new position in Royalty Pharma plc (NASDAQ:RPRX – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 163,200 shares of the biopharmaceutical company’s stock, valued at approximately $5,014,000.
Other hedge funds also recently bought and sold shares of the company. Captrust Financial Advisors increased its holdings in shares of Royalty Pharma by 210.8% during the 2nd quarter. Captrust Financial Advisors now owns 805 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 546 shares during the last quarter. Sageworth Trust Co acquired a new position in shares of Royalty Pharma during the 1st quarter valued at about $31,000. Parallel Advisors LLC increased its holdings in shares of Royalty Pharma by 454.6% during the 1st quarter. Parallel Advisors LLC now owns 904 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 741 shares during the last quarter. Altshuler Shaham Ltd acquired a new position in shares of Royalty Pharma during the 1st quarter valued at about $44,000. Finally, CWM LLC increased its holdings in shares of Royalty Pharma by 33.8% during the 1st quarter. CWM LLC now owns 2,080 shares of the biopharmaceutical company’s stock valued at $75,000 after acquiring an additional 526 shares during the last quarter. 49.03% of the stock is owned by institutional investors and hedge funds.
Royalty Pharma Stock Up 0.3 %
Shares of RPRX opened at $26.60 on Friday. Royalty Pharma plc has a 52 week low of $25.92 and a 52 week high of $44.47. The company has a debt-to-equity ratio of 0.64, a quick ratio of 13.51 and a current ratio of 13.51. The firm has a market capitalization of $15.89 billion, a P/E ratio of 85.81, a P/E/G ratio of 1.59 and a beta of 0.42. The company has a 50-day simple moving average of $27.34 and a 200-day simple moving average of $30.04.
Royalty Pharma Announces Dividend
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on the company. TheStreet downgraded Royalty Pharma from a “c” rating to a “d+” rating in a research note on Friday, November 10th. StockNews.com assumed coverage on shares of Royalty Pharma in a research report on Thursday, October 5th. They set a “hold” rating for the company. Finally, Morgan Stanley upped their price objective on shares of Royalty Pharma from $54.00 to $57.00 and gave the company an “overweight” rating in a research report on Thursday, November 9th. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $55.00.
Royalty Pharma Company Profile
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
- Five stocks we like better than Royalty Pharma
- What is the FTSE 100 index?
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Earnings Per Share Calculator: How to Calculate EPS
- MarketBeat Week in Review – 11/13 – 11/17
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.